# Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

- Link: https://www.directorstalkinterviews.com/hikma-enhances-injectables-pipeline-and-manufacturing-capabilities-with-xellia-acquisition/4121160453
- Published: 2024-06-17T07:20:22+01:00
- Author: Amilia Stone

**Hikma Pharmaceuticals PLC** (LON:HIK), the multinational pharmaceutical group,
has announced that it has agreed with Xellia Pharmaceuticals, a Copenhagen based
specialty company focusing on providing anti-infective treatments and other critical
care therapies, to acquire parts of its US finished dosage form (FDF) business and
assets, including a commercial portfolio and pipeline of differentiated products,
a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and
an R&D center in Zagreb, Croatia. Hikma will pay a cash consideration of $135 million,
and an additional contingent consideration of up to $50 million, subject to the 
achievement of certain regulatory and commercial milestones.

**Transaction highlights and strategic rationale:**

·    **Supports the long-term growth of Hikma’s Injectables business   **

·    **Diversifies and enriches Hikma’s US injectables portfolio and pipeline**,
adding a range of ready-to-use (RTU) products, including Vanco Ready^(®), which 
was launched in 2019

·    **Significantly expands Hikma’s high-quality manufacturing capacity.** The 
Cleveland facility is spread over 24 acres and, following a two-to-three-year enhancement
project, will significantly increase Hikma’s injectables capacity to accommodate
a growing US portfolio, with potential to leverage the facility for contract manufacturing

·    **Adds complex manufacturing technologies,** including aseptic premix bag filling
capabilities and a significant increase in lyophilization capacity

·    **Enhances Hikma’s R&D capabilities.** The R&D center in Zagreb, Croatia adds
an experienced team of R&D professionals with the track record and expertise to 
develop complex finished dosage forms. Hikma will leverage this expertise across
its global injectables markets

·    **Neutral to Group core earnings in the first 12 months following closing and
accretive thereafter, with meaningful longer-term benefits.** Upon closing, the 
current Xellia in-market products will immediately contribute around $75 million
revenue on an annualized basis.

**Acquired assets:**

The acquisition will add eight approved and marketed injectable products to Hikma’s
US portfolio and 11 pipeline products. The Xellia commercial portfolio comprises
the ready-to-use formulation, Vanco Ready^(®) (vancomycin), launched in 2019, and
other anti-infectives. These products are currently manufactured by a third-party
and Hikma will maintain these manufacturing contracts while it upgrades the Cleveland
facility, with the goal of moving production of these products in-house.

The Cleveland site offers end-to-end capabilities to develop, manufacture, pack 
and distribute lyophilized vials and aseptically filled ready-to-use IV bag products.
Hikma intends to undertake a series of investments to enhance productivity and efficiency
through the addition of automation, equipment, and updated processes. These investments
will be captured within Hikma’s existing annual capital expenditure plan. Hikma 
expects the facility to be operational within two to three years.

Hikma will also be acquiring Xellia’s R&D center in Zagreb, Croatia, including a
large team of professionals.  This center will bring a range of expertise including
developing innovative and generic products and finished dosage forms, primarily 
in premix RTU bags.

> **Riad Mishlawi, CEO commented**:
> “Hikma has grown to become a top-three US supplier of sterile injectable medicines
> thanks to our strong record of successfully making value-enhancing acquisitions
> like this one. This acquisition will add significant scale to our US operations
> and will enhance our US injectable manufacturing capabilities and portfolio by
> adding complex technologies. I am confident that this transaction will deliver
> significant future value to our Injectables business, supporting growth over the
> medium term.” 

> **Dr Bill Larkins, President of Hikma Injectables commented**:
> “This acquisition strengthens our Injectables business, and I am particularly 
> excited by the potential to further develop our pipeline with the talented and
> experienced team at the Zagreb R&D facility. The combination of Xellia’s assets
> with our quality manufacturing expertise and strong commercial capabilities puts
> us in an even stronger position to serve the growing needs of hospitals and patients.”

The transaction is subject to US Federal Trade Commission approval. Hikma’s 2024
guidance remains unchanged.

Share on:
